This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Nov 2020

Stelis starts next phase of investment into its biologics manufacturing facility

This phase sees the CDMO start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.

Contract development and manufacturing organization (CDMO), Stelis BioSource, a division of Stelis Biopharma, has started the next phase of its continued investment program after having already invested more than $100 million into its facilities in Bangalore, India.

The latest phase will see the company, which offers end-to-end development and manufacturing services for biologics and biosimilars companies, start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.

The bioreactor trains will be added to the company’s 200,000 sq ft state-of-the-art manufacturing facility which became fully operational earlier this year. The new manufacturing facility, which caters for drug product and drug substance manufacture, allows Stelis BioSource to offer fully integrated services from early phase development through to commercial manufacture and fill finish.

In addition to the drug substance and drug product capabilities, which cover process scale-up and cGMP manufacturing to commercial scales, the facility offers the latest analytical methodologies and equipment and operates under Stelis’ fully compliant quality management system.

Dr Roger Lias, CEO at Stelis Biopharma said: “Our CDMO facility in Bangalore is already fully operational working on both new and existing customer projects. The investment has been driven by both strong market demand and multiple opportunities to develop an offering for the delivery of affordable outsourced capabilities for biologics".

The company, which is dedicated to driving down the cost of biologics, also has plans to develop the site further. The company continues to evaluate further investments into both capabilities and capacity to meet customer demand, including for those driven by the current Covid-19 pandemic.


Stay at the cutting edge at CPHI Barcelona

All over the industry, companies are upscaling, innovating and progressing. If you want to stay up to date on the latest trends and developments, join us at CPHI Barcelona. Meet representatives from over 1800 businesses including new ventures in our Start-Up Market.

Your CPHI Barcelona pass gives you access to all conference sessions, including the Quality Management track, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!

Learn more

Mentioned Companies
Stelis Biopharma Pvt Ltd
View company profile

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.